New Market Report: Tuberculosis Infection - Pipeline Assessment and Market Forecasts to 2018

New Pharmaceuticals research report from GlobalData is now available from Fast Market Research

Logo

Williamstown, MA -- (SBWire) -- 12/01/2011 --GlobalData, the industry analysis specialist, has released its new report, "Tuberculosis Infection - Pipeline Assessment and Market Forecasts to 2018". The report is an essential source of information and analysis on the global tuberculosis infection market. The report identifies the key trends shaping and driving the global tuberculosis infection market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global tuberculosis infection sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

View Full Report Details and Table of Contents

The global Tuberculosis (TB) infection market was worth $38.3m in 2010. The market is expected to decline at a compound annual growth rate (CAGR) of 4.5% during the next eight years to reach $26.6m by 2018. The TB drugs market has been well served by antimycobacterial agents and antibiotics since the 1960s. The cure rates have been improved with the conventional DOTS (Directly Observed Therapy). Multi-Drug Resistant Tuberculosis (MDR-TB) has been a consequence of patient non-compliance and the long duration of therapy. Companies seem to be actively developing products for the prophylaxis and cure of TB with lesser treatment duration. The two not-for-profit organizations, TB Alliance and the Aeras Global TB Vaccine Foundation, have partnered with pharmaceutical players in order to develop novel therapies and vaccines that can provide better patient compliance and prevention against TB. However, the global TB drugs market is heading towards a phase of decline as no launches are expected until 2018. Further the prevalent and reported TB cases have also reduced due to increased access to the DOTS and DOTS-PLUS programs in developed countries.

Note: This is a on-demand report and will be delivered within 3 business days of the purchase (excluding weekends).

Scope

The report provides information on the key drivers and challenges of the tuberculosis infection market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) tuberculosis infection market revenues data from 2005 to 2010, forecast for eight years to 2018.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- Anti-Bacterials Market to 2016 - Cephalosporins, Penicillins, Macrolides and Fluoroquinolones to Drive the Anti-Bacterials Market
- Hepatitis B Vaccines - Pipeline Assessment and Market Forecasts to 2018
- Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2018
- Non-Small Cell Lung Cancer (NSCLC) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Epilepsy Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Chronic Kidney Disease (CKD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Tuberculosis Therapeutics - Pipeline Assessment and Market Forecasts to 2017
- Cancer Vaccines - Pipeline Assessment and Market Forecasts to 2018
- Hemophilia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
- Brain Hemorrhage Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Media Relations Contact

Bill Thompson
Director of Marketing
800-844-8156
http://www.fastmr.com

View this press release online at: http://rwire.com/116713